Interstitial lung disease (ILD) is a broad category of respiratory diseases, characterized by inflammation and scarring in the interstitium, the tissue surrounding the alveoli, the tiny air sacs where gas exchange occurs in the lungs. This scarring makes it difficult for oxygen to pass from the lungs into the bloodstream, leading to shortness of breath and fatigue. ILD encompasses over 200 distinct conditions, varying in cause, progression, and treatment, but all share the common feature of interstitial fibrosis.
Interstitial Lung Disease: An Overview
September 18 is Interstitial Lung Disease Day.
Symptoms and Diagnosis
The primary symptoms of ILD are dyspnea (shortness of breath) and cough. As the disease advances, patients may experience fatigue, weight loss, and chest pain. In severe cases, blue discoloration of the skin and lips (cyanosis) can occur due to inadequate oxygenation of the blood. Diagnosis of ILD involves a combination of medical history, physical examination, lung function tests, imaging studies, and sometimes biopsy. High-resolution computed tomography (HRCT) scans are particularly useful in visualizing the interstitial scarring. Lung function tests, such as spirometry and diffusion capacity, quantify the degree of lung impairment.
Treatment and Outcomes
Treatment of ILD depends on the underlying cause. For idiopathic pulmonary fibrosis (IPF), the most common type of ILD, there is no cure, and treatment focuses on slowing disease progression and managing symptoms. Medications such as nintedanib and pirfenidone can slow the rate of forced vital capacity decline. Oxygen therapy is often necessary to combat hypoxia. Pulmonary rehabilitation programs, which include exercise training, education, and support, can improve quality of life. Lung transplantation may be considered for advanced cases. The prognosis for ILD varies widely depending on the specific type and rate of progression.
Known Causes of ILD
Patients with some inflammatory and connective tissue diseases are at a higher risk for ILD. These conditions include many AiArthritis diseases like rheumatoid arthritis, systemic scleroderma, myositis, including dermatomyositis and polymyositis (DM and PM), sarcoidosis, and Sjögren's.
By Kelly Conway
Explore the latest discussion on early treatment for rheumatoid arthritis and what current research reveals about diagnosis, intervention, and long-term patient outcomes.
Discover the latest research on rheumatoid arthritis, including insights into disease risk, the importance of early treatment, and the connection between RA and lung disease.
Explore what emerging research is teaching us about difficult-to-treat and poly-refractory rheumatoid arthritis, including the challenges patients face when treatments stop working and the search for more personalized approaches to care.
Learn about VEXAS syndrome, a newly identified inflammatory condition linked to immune system dysfunction, and why greater awareness may help patients with complex or overlapping AiArthritis disease symptoms find answers sooner.